A Johansson


Country: Sweden


  1. request reprint
    Johansson A, Claesson R, Belibasakis G, Makoveichuk E, Hänström L, Olivecrona G, et al. Protease inhibitors, the responsible components for the serum-dependent enhancement of Actinobacillus actinomycetemcomitans leukotoxicity. Eur J Oral Sci. 2001;109:335-41 pubmed
    ..The degradation is caused by enzymes from degranulated PMNL triggered by leukotoxin. ..
  2. request reprint
    Johansson A, Johansson I, Eriksson M, Ahren A, Hallmans G, Stegmayr B. Systemic antibodies to the leukotoxin of the oral pathogen Actinobacillus actinomycetemcomitans correlate negatively with stroke in women. Cerebrovasc Dis. 2005;20:226-32 pubmed
    ..actinomycetemcomitans leukotoxin correlates negatively with a future stroke in woman, but not in men. Further studies are needed to explain the underlying mechanisms, as well as the biological relevance of this finding. ..
  3. request reprint
    Johansson A, Buhlin K, Koski R, Gustafsson A. The immunoreactivity of systemic antibodies to Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis in adult periodontitis. Eur J Oral Sci. 2005;113:197-202 pubmed
    ..gingivalis is frequent in adult periodontitis, while the role of A. actinomycetemcomitans seems to be more complex and depends on gender of the infected subject as well as the virulence of the bacteria. ..
  4. Johansson A. Aggregatibacter actinomycetemcomitans leukotoxin: a powerful tool with capacity to cause imbalance in the host inflammatory response. Toxins (Basel). 2011;3:242-59 pubmed publisher
    ..Therapeutic strategies targeting the cellular and molecular inflammatory host response in periodontal diseases might be a future treatment alternative. ..
  5. Johansson A, Eriksson M, Ahrén A, Boman K, Jansson J, Hallmans G, et al. Prevalence of systemic immunoreactivity to Aggregatibacter actinomycetemcomitans leukotoxin in relation to the incidence of myocardial infarction. BMC Infect Dis. 2011;11:55 pubmed publisher
    ..The results from the present study do not support the hypothesis that systemic leukotoxin-neutralizing capacity can decrease the risk for MI. ..
  6. Johansson D, Kosovac E, Moharer J, Ljuslinder I, Brannstrom T, Johansson A, et al. Expression of verotoxin-1 receptor Gb3 in breast cancer tissue and verotoxin-1 signal transduction to apoptosis. BMC Cancer. 2009;9:67 pubmed publisher
    ..The high specificity and apoptosis-inducing properties of verotoxin-1 indicates that the toxin potentially may be used for treatment of Gb3-expressing breast cancer. ..